Peony and Improved Complete Response Rate

Doses used in studies

Time to effect

Median: 12.2 months · IQR 12.2 months–12.2 months · Range 12.2 months–12.2 months — Reported in 1 of 1 study

Safety in these studies

diarrheaIncreased risk5.5% vs. 0.9%
The safety analysis primarily showed mild adverse events, with a higher incidence of diarrhea in the TGP group (5.5% vs. 0.9%)
from: Clinical effectiveness and safety of total glucosides of paeony as an immunomodulator in p
adverse events (mild)Reported
The safety analysis primarily showed mild adverse events, with a higher incidence of diarrhea in the TGP group (5.5% vs. 0.9%), but no severe events or treatment discontinuations.
from: Clinical effectiveness and safety of total glucosides of paeony as an immunomodulator in p
severe adverse eventsReportedSerious adverse event
but no severe events or treatment discontinuations.
from: Clinical effectiveness and safety of total glucosides of paeony as an immunomodulator in p

1 of 1 paper

Clinical effectiveness and safety of total glucosides of paeony as an immunomodulator in patients with refractory oral lichen planus: A multicenter, pragmatic, randomized controlled trial.